El interés en corto de Omnicell da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Omnicell. Los datos de interés en corto se actualizan cada dos semanas.

Omnicell (NASDAQ:OMCL) Bolsa, Informe de interés en corto

Omnicell

Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.

Omnicell Inc

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Wednesday.
The Dow traded up 0.07% to 42,262.68 while the NASDAQ fell 0.05% to 18,703.09. The S&amp;P 500 also fell, dropping, 0.03% to 5,831.09.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a>
Leading and Lagging Sectors Communication services shares rose by 1.8% on Wednesday.
In trading on Wednesday, information technology shares fell by 0.9%.
Top Headline
On Wednesday, Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) posted worse-than-expected third-quarter earnings and lowered 2024 guidance.
The U.S. pharma giant reported third-quarter revenue of $11.44 billion, up 20% year over year, but it missed the consensus of $12.10 billion. The company reported an adjusted EPS of $1.18, compared to $0.10 from a year ago and missing the consensus of $1.45.
Eli Lilly said it sees fiscal year 2024 sales of $45.4 billion—$46 billion, compared to prior guidance of $45.4 billion—$46.6 billion and consensus of $46.24 billion. Eli Lilly lowered its 2024 adjusted EPS guidance to $13.02-$13.52 versus prior guidance of $16.10-$16.60 and consensus of $13.47, driven by the acquired IPR&amp;D charges incurred in Q3.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Tharimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares shot up 79% to $3.61 after the company announced it received EMA feedback on its TH104 clinical program. The design and main features of the proposed Phase 2 study were deemed acceptable and general guidance was also provided for a future Phase 3 study.</li>
<li>Shares of Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) got a boost, surging 31% to $52.47 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares were also up, gaining 44% to $117.36 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Equities Trading DOWN</h3>
<ul>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares dropped 55% to $0.0304 after the company announced it upsized its $6.8 million public offering.</li>
<li>Shares of The Container Store Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TCS#NYSE">TCS</a>) were down 37% to $5.27 following second-quarter results.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) was down, falling 39% to $0.1938 after the company announced the pricing of a registered direct offering of 20,312,500 shares at $0.32 per share. The company also announced a concurrent private placement.</li>
</ul>
Commodities In commodity news, oil traded up 2.3% to $68.75 while gold traded up 0.7% at $2,799.70.
Silver traded down 1% to $34.095 on Wednesday, while copper rose 0.1% to $4.3640.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 dipped 1.25%, Germany's DAX fell 1.13% and France's CAC 40 slipped 1.10%. Spain's IBEX 35 Index fell 0.68%, while London's FTSE 100 fell 0.73%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 gaining 0.96%, Hong Kong's Hang Seng Index dipping 1.55%, China's Shanghai Composite Index falling 0.61% and India's BSE Sensex falling 0.53%.
Economics
<ul>
<li>Pending home sales in the U.S. surged by 7.4% from the previous month in September, compared to a 0.6% gain in August.</li>
<li>The U.S. economy grew by an annualized 2.8% in the third quarter, from 3% in the second quarter.</li>
<li>Private businesses in the U.S. hired 233K workers to their payrolls in October compared to a revised 159K gain in September. </li>
<li>Crude oil inventories in the U.S. declined by 0.515 million barrels in the week ended October 25, compared to a 5.474 million gain in the prior week and versus market estimates of a 2.3 million gain.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41623120/jim-cramer-says-buy-crowdstrike-stock-calls-this-aerospace-manufacturer-is-a-high-specul">Jim Cramer Says Buy CrowdStrike Stock, Calls This Aerospace Manufacturer A &#8216;High Speculative&#8217; Stock</a></li>
</ul>

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

APDN

OMCL

RDDT

SVMH

THAR

Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast

U.S. stocks traded mixed midway through trading, with the S&amp;P 500 edging lower on Wednesday.
The Dow traded up 0.08% to 42,267.94 while the NASDAQ fell 0.15% to 18,684.06. The S&amp;P 500 also fell, dropping, 0.07% to 5,828.67.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a>
Leading and Lagging Sectors Communication services shares rose by 1.8% on Wednesday.
In trading on Wednesday, information technology shares fell by 1%.
Top Headline 
Crude oil inventories in the U.S. declined by 0.515 million barrels in the week ended October 25, compared to a 5.474 million gain in the prior week and versus market estimates of a 2.3 million gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Tharimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares shot up 104% to $4.13 after the company announced it received EMA feedback on its TH104 clinical program. The design and main features of the proposed Phase 2 study were deemed acceptable and general guidance was also provided for a future Phase 3 study.</li>
<li>Shares of Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) got a boost, surging 37% to $54.78 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares were also up, gaining 42% to $115.96 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares dropped 58% to $0.0287 after the company announced it upsized its $6.8 million public offering.</li>
<li>Shares of Vicinity Motor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) were down 48% to $0.0252. Vicinity Motor recently announced that all members of its board of directors have resigned.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) was down, falling 38% to $0.1975 after the company announced the pricing of a registered direct offering of 20,312,500 shares at $0.32 per share. The company also announced a concurrent private placement.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $68.23 while gold traded up 0.4% at $2,792.20.
Silver traded down 1.3% to $34.00 on Wednesday, while copper rose 0.1% to $4.3625.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 1%, Germany's DAX fell 0.27% and France's CAC 40 slipped 0.61%. Spain's IBEX 35 Index fell 0.6%, while London's FTSE 100 fell 0.80%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 gaining 0.96%, Hong Kong's Hang Seng Index dipping 1.55%, China's Shanghai Composite Index falling 0.61% and India's BSE Sensex falling 0.53%.
Economics
<ul>
<li>Pending home sales in the U.S. surged by 7.4% from the previous month in September, compared to a 0.6% gain in August.</li>
<li>The U.S. economy grew by an annualized 2.8% in the third quarter, from 3% in the second quarter.</li>
<li>Private businesses in the U.S. hired 233K workers to their payrolls in October compared to a revised 159K gain in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41623120/jim-cramer-says-buy-crowdstrike-stock-calls-this-aerospace-manufacturer-is-a-high-specul">Jim Cramer Says Buy CrowdStrike Stock, Calls This Aerospace Manufacturer A &#8216;High Speculative&#8217; Stock</a></li>
</ul>

Earnings

S&P 500 Edges Lower; US Crude Oil Inventories Fall

<h3>Gainers</h3>
<ul>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 106.1% to $4.18 during Wednesday's regular session. The market value of their outstanding shares is at $4.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 51.76% to $0.63. The company's market cap stands at $9.3 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock rose 35.29% to $1.34. The company's market cap stands at $58.8 million. </li>
<li>Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) stock rose 33.25% to $53.46. The company's market cap stands at $2.4 billion. The company's, Q3 earnings came out today. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 32.83% to $14.27. The company's market cap stands at $309.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares rose 31.66% to $5.17. The company's market cap stands at $55.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 37.0% to $0.2 during Wednesday's regular session. The company's market cap stands at $2.0 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) stock declined by 25.56% to $22.93. The company's market cap stands at $692.4 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined by 20.46% to $6.75. The market value of their outstanding shares is at $411.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) shares decreased by 20.14% to $24.36. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares declined by 15.32% to $10.98. The market value of their outstanding shares is at $613.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 15.06% to $18.89. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ANAB

CALC

CRMD

CVRX

ENSC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OPCH

SAGE

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.
Shares of Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) gained 13.5% to $12.38 following better-than-expected <a href="https://www.benzinga.com/news/earnings/24/10/41627569/snap-stock-is-surging-today-whats-going-on">quarterly financial results.</a>
Snap reported third-quarter revenue of $1.373 billion, beating the consensus estimate of $1.358 billion, according to Benzinga Pro. The social media company reported adjusted earnings of 8 cents per share, beating analyst estimates of 5 cents per share.
Snap shares jumped 13.5% to $12.38 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares jumped 41.3% to $115.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) gained 37% to $54.99 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates.</li>
<li>Unisys Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) surged 30.7% to $7.03 after the company reported better-than-expected third-quarter sales results and raised its FY24 non-GAAP operating profit margin guidance.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) rose 30.7% to $7.53 after the company announced that it has entered into a term sheet with TerraPower for the construction of a HALEU production facility.</li>
<li>NerdWallet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) gained 27.3% to $14.41 after the company reported better-than-expected quarterly revenue results.</li>
<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) surged 23% to $36.21 after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $34 to $40.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) gained 22.9% to $204.48 after the company reported better-than-expected third-quarter financial results and raised annual outlook.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) surged 14.6% to $32.92 after the company reported better-than-expected quarterly financial results and raised its FY24 sales guidance above estimates.</li>
<li>The Cheesecake Factory Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) gained 13.6% to $48.69 after the company reported better-than-expected quarterly adjusted EPS results. Also, multiple firms raised their respective price targets on the stock.</li>
<li>Adtalem Global Education Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NASDAQ">ATGE</a>) rose 12.7% to $84.53 following first-quarter results.</li>
<li>FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) gained 11.5% to $67.12 following better-than-expected quarterly earnings.</li>
<li>OneMain Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) rose 10.8% to $52.63 following strong quarterly earnings.</li>
<li>Smurfit Westrock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) gained 10.4% to $49.38 following third-quarter results.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) surged 6.2% to $129.21.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) gained 5.3% to $180.25 following better-than-expected third-quarter earnings.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41623120/jim-cramer-says-buy-crowdstrike-stock-calls-this-aerospace-manufacturer-is-a-high-specul">Jim Cramer Says Buy CrowdStrike Stock, Calls This Aerospace Manufacturer A &#8216;High Speculative&#8217; Stock</a></li>
</ul>

ASPI

Adtalem Global Education Inc. Common Stock

ATGE

ATRC

CAKE

DELL

EXEL

GOOG

GRMN

NRDS

SNAP

Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday

WIIM

Omnicell shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 guidance above estimates. Also, the company issued Q4 guidance above estimates.

For the fourth quarter of 2024, the Company expects total revenues to be between $295 million and $305 million. The Company expects fourth quarter 2024 product revenues to be between $177 million and $182 million, and fourth quarter 2024 service revenues to be between $118 million and $123 million. The Company expects fourth quarter 2024 non-GAAP EBITDA to be between $40 million and $45 million. The Company expects fourth quarter 2024 non-GAAP earnings per share to be between $0.55 and $0.62 per share.

Guidance

Omnicell Expects Q4 Revenue Of $295M-$305M Vs $287.89M Est, Adj EPS Of $0.55-$0.62 Vs $0.47 Est

Based on strong performance during the first three quarters of 2024 and current visibility of the business, the Company is updating the previously provided 2024 annual guidance ranges. For the full year 2024, the Company expects bookings to be between $800 million and $875 million. The Company expects full year 2024 total revenues to be between $1.100 billion and $1.110 billion. The Company expects full year 2024 product revenues to be between $625 million and $630 million, and full year 2024 service revenues to be between $475 million and $480 million. The Company expects full year 2024 technical services revenues to be between $236 million and $238 million, and full year 2024 Advanced Services revenues to be between $239 million and $242 million. The Company expects full year 2024 non-GAAP EBITDA to be between $129 million and $134 million. The Company expects full year 2024 non-GAAP earnings per share to be between $1.65 and $1.72 per share.

Omnicell Sees FY24 Revenues Of $1.10B-$1.11B (Prior $1.07B-$1.110B) Vs. $1.09B Estimate With Adj EPS Of $1.65-$1.72 (Prior $1.20-$1.50) Vs. $1.37 Estimate

Earnings Beats

Omnicell Q3 2024 Adj. EPS $0.56 Beats $0.40 Estimate, Sales $282.420M Beat $280.448M Estimate

Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Equal-Weight and raises the price target from $30 to $41.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Omnicell, Raises Price Target to $41

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;
<h3>1. Teladoc Health</h3>
Market Cap: $1.4 Billion
Focus Area: Telehealth&nbsp;
Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.
What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.
<h3>2. WELL Health Technologies</h3>
Market Cap: $1.1 Billion
Focus Area: Digital Health Solutions&nbsp;
WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;
WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.
<h3>3. Omnicell</h3>
Market Cap: $1.9 Billion
Focus Area: Automation and analytics
Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.
What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.
<h3>4. IRadimed Corporation&nbsp;</h3>
Market Cap: $700 Million
Focus Area: MRI-Compatible Devices
IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.
With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.
<h3>5. Evolent Health Inc.</h3>
Market Cap: $1.3 Billion
Focus Area: Value-Based Care
Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.
With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.
<h3>6. CareDx, Inc.</h3>
Market Cap: $520 Million
Focus Area: Transplant Diagnostics
CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.
CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.
<h3>7. Tactile Systems Technology, Inc.</h3>
Market Cap: $450 Million
Focus Area: Chronic Disease Management
Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.
Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.
<h4>Conclusion:</h4>
the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Small Cap

CDNA

IRMD

TCMD

TDOC

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

Ratings for Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.33, along with a high estimate of $48.00 and a low estimate of $30.00. This upward trend is evident, with the current average reflecting a 19.18% increase from the previous average price target of $33.00.
<img src="https://www.benzinga.com/files/images/story/2024/1728486060_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Omnicell by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Omnicell. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Omnicell compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Omnicell's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Omnicell's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OMCL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omnicell analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Omnicell Better</h2>
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
<h3>Key Indicators: Omnicell's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Omnicell faced challenges, resulting in a decline of approximately -7.42% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Omnicell's net margin excels beyond industry benchmarks, reaching 1.35%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Omnicell's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omnicell's ROA stands out, surpassing industry averages. With an impressive ROA of 0.16%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Omnicell's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.51.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Omnicell In The Eyes Of 6 Experts

Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Buy and maintains $48 price target.

Reiteration

Benchmark Reiterates Buy on Omnicell, Maintains $48 Price Target

Management

Omnicell Names Nnamdi Njoku As Executive Vice President And COO, Effective October 7, 2024

Analysts' ratings for Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.6, along with a high estimate of $44.00 and a low estimate of $30.00. Marking an increase of 25.33%, the current average surpasses the previous average price target of $30.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1724421639_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Omnicell by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omnicell. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omnicell compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Omnicell's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Omnicell's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OMCL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omnicell analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Omnicell's Background</h2>
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
<h3>Financial Milestones: Omnicell's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Omnicell faced challenges, resulting in a decline of approximately -7.42% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Omnicell's net margin is impressive, surpassing industry averages. With a net margin of 1.35%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Omnicell's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omnicell's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Omnicell adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 5 Takes On Omnicell

JP Morgan analyst Anne Samuel maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Neutral and raises the price target from $26 to $37.

JP Morgan Maintains Neutral on Omnicell, Raises Price Target to $37

Omnicell, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) recently announced Central Med Automation Service, a subscription-based solution. It is designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers (&quot;CPSCs&quot;) and similar operations.&nbsp;
<h3>About Central Med Automation Service</h3>
Intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, this solution is expected to improve inventory visibility, scalability and patient safety.
The traditional methods of medication management can lead to multi-vendor environments that may complicate workflows, often creating unnecessary redundancy and increasing chances of error.Pharmacy leaders often lack the capital budgets, resources and expertise necessary to transform their infrastructure and scale it over time. Omnicell&#39;s Central Med Automation Service is designed to help health systems develop and execute a central fill strategy while providing the support necessary to ensure this environment meets the current and future medication management needs.
<h3>Features of Central Med Automation Service</h3>
Central Med Automation Service helps seamlessly integrate enterprise-wide robotics, smart devices and intelligent software with expert services.
Within the Robotics &amp; Smart Devices segment, Central Med Automation Service contains XR2 Automated Central Pharmacy System, which is aimed to improve inventory visibility, efficiency and patient safety. In the software segment, Central Med Automation Service has the Central Pharmacy Manager software, designed to support centralized medication management workflows within a CPSC, including medication ordering, receiving, picking, verifying and restocking.&nbsp;
Additionally, it also comes with an Inventory Optimization Service &mdash;a combination of software and expert services. This solution helps provide enterprise-wide inventory visibility and management of medication par levels, expiration dates and usage patterns delivered through data-rich dashboards.
The expert services include tailored guidance from Omnicell experts and dedicated on-site assistance to operate robotics and smart devices. Omnicell expert services utilize data analytics to deliver operational performance metrics, facilitating informed decision-making and continuous improvement in efficiency.
<h3>More on the News</h3>
Central Med Automation Service&#39;s capabilities can be extended by adding several complementary robotics, smart devices and software tools. These include Omnicell&#39;s suite of pharmacy carousels and packagers, 340B program management software and Central Pharmacy Manager Mobile Workstation.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/db/74860.jpg?v=1510659719" />
Image Source: Zacks Investment Research
<h3>Industry Prospects</h3>
Per a Grand View Research report, the global medical automation market was valued at $44.44 billion in 2022 and is expected to witness a CAGR of 9.04% from 2023 to 2030. Primary factors driving the market include the adoption of automated instruments by drug discovery departments of pharmaceutical companies, the rise in need for miniaturization, and technological advancements, coupled with the rise in demand for robot-assisted surgeries.
Looking at the market potential, it can be seen that the latest development is well-timed and beneficial for Omnicell&#39;s growth.
<h3>Another Recent Development</h3>
Earlier this year, Omnicell introduced XT Amplify &mdash; a multi-year innovation program that is intended to maximize value for hospitals, health systems and post-acute care facilities that have invested in Omnicell&#39;s XT Automated Dispensing System.
<h3>Price Performance</h3>
Year to date, shares of OMCL have risen 12.1% against the industry&#39;s 10.6% decline.
<h3>Zacks Rank and Key Picks</h3>
Omnicell currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and Quest Diagnostics (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2 (Buy).
Intuitive Surgical&#39;s shares have surged 68.3% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.
ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics&#39; 2024 EPS have moved up 48.1% to $1.20 cents in the past 30 days. Shares of the company have soared 153.2% in the past year compared with the industry&#39;s 12.6% growth.
TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Quest Diagnostics&#39; 2024 EPS have increased 0.3% to $8.88 in the past 30 days. In the past year, shares of HAE have risen 14% compared with the industry&#39;s 21.2% growth.
In the last reported quarter, DGX delivered an earnings surprise of 1.73%. The company has a trailing four-quarter average earnings surprise of 3.31%.
<a href="https://www.zacks.com/stock/news/2325052/omnicell-omcl-introduces-central-med-automation-service?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2325052">To read this article on Zacks.com click here.</a>

Biotech

Large Cap

Mid Cap

General

ISRG

TMDX

Omnicell Introduces Central Med Automation Service

Full-Service, Scalable Solution Designed to Help Health Systems Establish and Continuously Optimize Centralized Medication Management Operations
Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>), a leader in transforming the pharmacy care delivery model, today announced Central Med Automation Service, a subscription-based solution designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers (CPSCs) and similar operations. Central Med Automation Service is intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, which is expected to enhance inventory visibility, scalability, and patient safety.

Omnicell Announces Central Med Automation Service, A Subscription-Based Solution Designed To Help Health Systems Establish And Continuously Optimize Centralized Medication Management For CPCS And Similar Operations

Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Equal-Weight and raises the price target from $26 to $30.

Wells Fargo Maintains Equal-Weight on Omnicell, Raises Price Target to $30

B of A Securities analyst Allen Lutz maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Buy and raises the price target from $34 to $44.

B of A Securities Maintains Buy on Omnicell, Raises Price Target to $44

Barclays analyst Stephanie Davis upgrades Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Underweight to Equal-Weight and raises the price target from $26 to $39.

Upgrades

Barclays Upgrades Omnicell to Equal-Weight, Raises Price Target to $39

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Omnicell (OMCL – Research Report). The company's shares closed...

Craig-Hallum Sticks to Its Buy Rating for Omnicell (OMCL)

Analyst Stan Berenshteyn of Wells Fargo maintained a Hold rating on Omnicell (OMCL – Research Report), retaining the price target of $30.00. Stan B...

Hold Rating on Omnicell Amid Modest Growth Prospects and Uncertain Sales Trajectory

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pulmonx (LUNG – Research Report), Omnicell (OMCL – R...

Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Omnicell (OMCL)

Analyst Stan Berenshteyn of Wells Fargo maintained a Hold rating on Omnicell (OMCL – Research Report), boosting the price target to $41.00. Stan Be...

Omnicell: A Hold Rating with a Cautiously Optimistic Long-Term Outlook

Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Omnicell (OMCL – Research Report) today. The company's shares closed yesterday at $40.3...

Craig-Hallum Sticks to Their Buy Rating for Omnicell (OMCL)

Omnicell Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Omnicell beats Q3 top and bottom line estimates

Omnicell, Inc. 2024 Q3 - Results - Earnings Call Presentation

Omnicell, Inc. (OMCL) Q3 2024 Earnings Call Transcript

ARVN

AXTA

BASFY

BIIB

BLKB

BPMC

COCO

CRTO

CVEO

CWEN

EADSF

ENIC

EXTR

FLEX

FVRR

GEHC

HESM

INMD

ITCI

IVPAF

LKNCY

LUNG

NAVI

NBIX

NVCR

OTIS

PUMP

ROCK

Press Releases

Omnicell to Present at the BofA Securities 2024 Health Care Conference

Omnicell Supports Global Charity Mercy Ships with Pharmacy Technology Donation

Omnicell to Release Second Quarter 2024 Financial Results on August 1, 2024

Omnicell Announces Second Quarter 2024 Results

EnlivenHealth® and Good Neighbor Pharmacy® Seek to Empower Independent Pharmacies with New Clinical Scope of Practice and Reimbursement Solution

Omnicell to Present at the 2024 Wells Fargo Healthcare Conference

Omnicell Announces Central Med Automation Service

Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

Comments

Omnicell

Interés en corto

Omnicell (NASDAQ:OMCL) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL